Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

Shares of Hims & Hers Health (NYSE:HIMS) reached a session low on Friday after a bipartisan group of U.S. lawmakers urged the ...

The healthcare worker warns that most people will put two thirds of the weight back on within a year of coming off the ...

China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...

Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer Lykke Hinsch Gylvin, M.D., set out the German drugmaker's plans to launch ...